Suggested remit - To appraise the clinical and cost effectiveness of treosulfan with fludarabine within its marketing authorisation as a conditioning treatment for malignant diseases prior to allogeneic haematopoietic stem cell transplantation
Status In progress
Process STA 2018
ID number 1508

Provisional Schedule

Final appraisal document 02 July 2020 - 16 July 2020
Expected publication 05 August 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Medac
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Anthony Nolan
  Lymphoma Action
  Leukaemia Care
Professional groups Royal College Of Radiologist
  Royal College of Physicians


General commentators All Wales Therapeutics and Toxicology Centre
  Department of Health and Social Services and Public Safety, Northern Ireland (DHSSPSNI)
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
18 March 2020 NICE released a positive ACD recommendation for treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant on 14 January 2020. NHS England have an interim funding agreement in place for treosulfan however Medac Pharma have indicated that supplies of treosulfan are expected to be available from 1st April 2020. Treosulfan will be made available for use when there are supplies.
14 January 2020 - 04 February 2020 Appraisal consultation
12 November 2019 Committee meeting: 1
14 March 2019 Invitation to participate
13 March 2019 In progress. In progress
09 November 2018 - 07 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance